Value in Health · 2020 · 44 citations · 27 references
PharmacyEconomicsPharmacoeconomicsDiabetologyHealth EconomicsPharmacoeconomic ModelingCardiovascular DiseaseDecision-analytic ModelingDiabetes MellitusEconomic EvaluationModel-based Economic EvaluationPharmacoeconomic EvaluationBias In Economic EvaluationCardiovascular Outcome TrialsChronic Disease Cost ModelingCost-utility Analysis InputsDisease Management EconomicsHealth Economic Decision ModelingPharmacoeconomic Simulation
27
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text